glp 1 agonist dpp 4 inhibitor Frontiers A Comprehensive Review on Dipeptidyl

Initial effects of retatrutide during this phase are primarily gastrointestinal, with appetite suppression developing before cardiovascular effects become noticeable

Real-world data from the FDA Adverse Event Reporting System shows that 77.44% of gastrointestinal side effects occur within the first 30 days, with a median onset time of just 1 day

For patients with chronic kidney disease, heart failure, or established atherosclerotic cardiovascular disease, substituting a sodium-glucose cotransporter 2 (SGLT2) inhibitor may be preferred

J Mol Neurosci

Gudin B, Ladhari C, Robin P, Laroche ML, Babai S, Hillaire-Buys D, et al

High-Risk Drug Classes and Interaction Concerns Not all medications are equally affected when used alongside GLP-1 therapies